Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ticlatone is a small molecule antifungal agent belonging to the benzothiazole class, characterized by a benzene ring fused to a thiazole ring. Its molecular formula is C7H4ClNOS and it has been primarily used for topical treatment of fungal infections (mycoses). Ticlatone has demonstrated efficacy against various fungal strains and may also possess moderate antibacterial activity. The precise mechanism of its antifungal action remains under investigation, but it is believed to disrupt cellular processes in fungi, inhibiting their growth and proliferation. Ticlatone reached up to Phase II clinical trials for dermatological use as an antifungal.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ticlatone.